EcoDrugPlus

Advanced Glycosylation End-Product Specific Receptor

Ensembl ID : ENSSTOG00000014729
Gene Symbol: AGER
3 Cross references
169 Possible Orthologues:

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSSTOG00000006233
Gene Symbol: ADH5
3 Cross references
400 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSSTOG00000012371
Gene Symbol: AKR1B1
2 Cross references
428 Possible Orthologues:

Amine Oxidase Copper Containing 1

Ensembl ID : ENSSTOG00000020269
Gene Symbol: AOC1
3 Cross references
230 Possible Orthologues:

Amine Oxidase Copper Containing 3

Ensembl ID : ENSSTOG00000034249
Gene Symbol: AOC3
3 Cross references
319 Possible Orthologues:

Amyloid P Component, Serum

Ensembl ID : ENSSTOG00000022183
Gene Symbol: APCS
3 Cross references
440 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSSTOG00000008660
Gene Symbol: APP
3 Cross references
276 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSSTOG00000021280
Gene Symbol: AR
4 Cross references
277 Possible Orthologues:

Angiotensin I Converting Enzyme

Ensembl ID : ENSSTOG00000009371
Gene Symbol: ACE
4 Cross references
93 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSSTOG00000025945
Gene Symbol: AGTR1
4 Cross references
206 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSSTOG00000012524
Gene Symbol: AGTR2
4 Cross references
191 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSSTOG00000021177
Gene Symbol: APLNR
3 Cross references
171 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).